ArticleTranslational cancer research2025

Long-term partial response after camrelizumab plus chemotherapy induction therapy and camrelizumab maintenance therapy beyond two years in squamous non-small cell lung cancer: a case report.

Li-Min Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.